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We investigated a prognostic signiﬁcance and the mechanism of aberrant nuclear expression of EZH2, a
histone methyltransferase, in human renal cell carcinoma (RCC). We found nuclear EZH2 in 48 of 100
RCCs and it was signiﬁcantly correlated with worse survival in RCC patients. We detected a decreased
expression of miR-101 in 15 of 54 RCCs. We found that re-expression of miR-101 resulted in EZH2 deple-
tion and decreased renal cancer cell proliferation. Our results show nuclear EZH2 as a prognostic marker
of worse survival in human RCC, and identify miR-101 as a negative regulator of EZH2 expression and
renal cancer cell proliferation.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Kidney cancer is the sixth and eighth most common cause of
cancer for men and women, respectively [1]. About 30% of patients
with renal cell carcinoma (RCC) are diagnosed with metastatic dis-
ease at initial presentation and up to 50% of RCC patients develop
metastases after surgical resection of tumor [2]. Currently, immu-
notherapy is the only available systemic therapy for metastatic
RCC showing some effect in less than 20% of metastatic RCC pa-
tients [3,4]. Recently, molecular targeted drugs emerged as the
treatment option for advanced RCC [5], which have been shown
to improve RCC patients survival [5]. However, the response to
these drugs is only partial [6] and is associated with severe toxicity
in RCC patients [7]. Thus, the identiﬁcation of new therapeutic tar-
gets and development of new approaches for the treatment of ad-
vanced RCC is urgently needed.
Enhancer of zeste homolog 2 (EZH2), a histone methyltransfer-
ase, is a catalytic subunit of a Polycomb Repressive Complex 2
(PRC2) which methylates histone H3 on lysine 27 [8]. EZH2 is in-
volved in epigenetic silencing of large number of genes involved
in differentiation and proliferation and is essential for embryonic
development [9]. Recent studies suggest EZH2 overexpression as
an important positive regulator of cancer cell growth in multiple
human malignancies [8] including prostate [10], bladder [11],
breast [12], colorectal [13] and pancreatic cancer [14]. However,Y-NC-ND license. 
.V. Ugolkov), ytomita@med.the role of EZH2 in RCC remains controversial. Whereas Wagener
et al. [15] study showed EZH2 nuclear overexpression as an inde-
pendent unfavorable marker of cancer speciﬁc survival in RCC pa-
tients, Hinz et al. [16] reported that high mRNA levels of EZH2 in
RCCs indicate less aggressive tumor phenotypes with a favorable
prognosis in RCC patients.
Here, our objective was to investigate a prognostic signiﬁcance
and the mechanism of aberrant nuclear expression of EZH2 in RCC.
We found nuclear accumulation of EZH2 as a prognostic marker of
worse survival in RCC, identiﬁed EZH2 as a positive regulator of re-
nal cancer cell proliferation, showed miR-101 as a negative regula-
tor of EZH2 expression in renal cancer cells, and demonstrated
p27Kip1 tumor suppressor as EZH2 target gene. Our study suggests
EZH2 as a potential therapeutic target and miR-101 overexpression
as a new approach to target EZH2 in the treatment of RCC.2. Materials and methods
2.1. Patients
The study was approved by the Ethical Committee of Yamagata
University and all patients signed an informed consent form. Sur-
gical specimens from 110 patients who underwent surgery from
2003 to 2008 at the Yamagata University Hospital were included
in the study. RCC patients’ clinical characteristics are presented
in the Table 1. The longest followed up was 105.4 months (median
39.7 months). Survival analysis was done for patients without
metastases at the time of operation.
Table 1
Patients’ clinical characteristics.
Median age (range) years 63 (25–87)
Male/female 73/37
Affected side (right/left) 60/50
Surgery
Laparoscopic/open 48/62
Radical/partial nephrectomy 73/37
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Monoclonal mouse antibody against EZH2 and p27Kip1 (BD
Transduction, San Diego, CA) were used for immunohistochemicalA
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Fig. 1. EZH2 is overexpressed in the nuclei of renal cancer cells. (A–B) Immunohistochem
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Western immunoblotting. (E) Distribution of EZH2 nuclear expression in different stag
patients.analysis. The staining was performed as described previously [17].
Detection was performed by peroxidase method using Histoﬁne
simple stain MAX-PO MULTY (Nichirei, Tokyo, Japan) and DAB in
the presence of H2O2. EZH2 nuclear accumulation was deﬁned as
positive staining of more than 50% of cancer cell nuclei throughout
the tumor regardless of cytoplasmic staining.2.3. Cell culture and RNA interference
Renal cancer cell lines ACHN, KRC/Y, Caki1, Caki2, A704, A498,
and KH39 were obtained from ATCC. KU19-20 was kindly provided
by Dr. Mototsugu Oya (Department of Urology, School of Medicine,
Keio University, Tokyo, Japan). The cells were cultured as describedB
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Table 2
Analysis of EZH2 expression in renal tumors.
Total EZH2 positive
Histological type Clear cell 92 37 (40%)
Papillary 6 3 (50%)
Chromophobe 1 1 (100%)
Cystic 5 3 (60%)
Unclassiﬁed 6 4 (67%)
pT stage 1a 57 23 (40%)
1b 22 9 (41%)
2 8 5 (63%)
3a 14 8 (57%)
3b 9 3 (33%)
pN status N() 107 45 (42%)
N(+) 3 3 (100%)
cM M() 100 46 (43%)
M(+) 10 2 (20%)
Fuhrman gradea 1 57 14 (25%)
2 34 20 (59%)
3 12 9 (75%)
4 7 5 (71%)
Total 110 48 (44%)
a Fuhrman grade, Fisher’s exact test p < 0.001, chi square 18.619. Fuhrman grade
1 vs. 2–4 Fisher’s exact test p < 0.001, chi square 15.929. Fuhrman grades 1–2 vs. 3–
4 Fisher’s exact test p = 0.004, chi square 7.
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eration assay as described previously [17]. Anti-EZH2 siRNA
(Dharmacon, Thermo Fisher Scientiﬁc K.K, Yokohama, Japan) and
unrelated control siRNA (Invitrogen, Life Technologies Corporation,
Tokyo, Japan) were used for genetic knockdown experiments.
Precursor miRNA, pre-miR-101 (Applied Biosystems Japan, Tokyo,
Japan) was used for cell transfection using Lipofectamine 2000
(Invitrogen).
2.4. Immunoblot analysis
Western blotting analysis was performed as described previ-
ously [17]. Nuclear/cytoplasmic protein separation was performed
by Dignam method as described previously [14]. The following
antibodies were used: anti-EZH2 and anti-p27Kip1 (BD Transduc-
tion); anti-Histone H3 (SIGMA, Saint Louis, Missouri); anti-tri-
methyl-Histone H3(Lys27) (Upstate Cell Signaling Solutions,
Temecula, CA); anti-Cu/Zn SOD (Stressgen, Ann Arbor, MI); anti-
b-actin (Abcam, Cambridge, MA).
2.5. MicroRNA extraction and real-time qRT-PCR
Total cellular RNA (including microRNA) from surgical speci-
mens immersed in RNAlater (Applied Biosystems, Tokyo, Japan)
tissue storage solution and stored at 80 C and cultured cell lines
was extracted using mirVanaTM miRNA Isolation Kit (Applied Bio-
systems Japan, Tokyo, Japan) and the ﬁrst strand DNA was synthe-
sized using a Taqman MicroRNA RT Kit (Applied Biosystems Japan,
Tokyo, Japan). For real-time quantitative RT-PCR we used TaqMan
MicroRNA Assays (Applied Biosystems) targeting human microR-
NA101 and RNU6B(U6) small nuclear RNA as an endogenous con-
trol. The expression of miRNA was calculated using the
comparative Ct (2-delta-delta Ct) method [18]. Each reaction was
run in triplicate and mean with SD were calculated. If the normal-
ized value was signiﬁcantly (p < 0.05) lower than normal kidney
counterpart, the miR-101 expression in tumor was considered
decreased.
2.6. Statistical analysis
All continuous variables in the present study met the criteria for
a normal distribution and were analyzed using a two tailed t-testor one-way ANOVA. Categorical data were analyzed using Fisher’s
exact test. For survival analysis of the patients Kaplan–Meier
curves for EZH2 negative and positive tumors were generated
and compared using Logrank test. Data were analyzed using SPSS
for Windows.3. Results
3.1. EZH2 nuclear accumulation is a strong predictor of worse survival
in RCC patients
By immunohistochemical analysis, we found EZH2 nuclear
expression selectively in cancer cells in surgically resected RCCs,
whereas EZH2 expression was not detectable in normal renal tis-
sues (Fig 1A–C). EZH2 expression was found in the nucleus with
no detectable cytoplasmic staining in cancer cells within surgically
resected RCCs (Fig 1A and C). We detected positive EZH2 staining
in 48 of 110 (44%) examined RCCs. We found that positive EZH2
staining correlated with higher Fuhrman nuclear grade of RCC (Ta-
ble 2, Fisher’s exact test p < 0.001, chi square 18.619). We found
nuclear expression of EZH2 in RCC cell lines by nuclear/cytosol
fractionation (Fig. 1D). We found that the percentage of EZH2-po-
sitive RCCs increased from stage T1a to T2 and T3. Positive EZH2
staining was signiﬁcantly associated with older age of RCC patients
(Fig. 1F, p < 0.001). We found that EZH2 nuclear expression pre-
dicted a shorter overall (Fig. 2A, p = 0.036) and recurrence-free
(Fig. 2B, p = 0.022) survival of RCC patients. These results suggest
EZH2 nuclear accumulation as a feature of renal cancer cells and
an indicator of worse survival in RCC patients.
3.2. Depletion of EZH2 leads to re-expression of p27Kip1 and
suppression of renal cancer cell proliferation
Although our results show nuclear accumulation of EZH2 as a
feature of renal cancer cells, its role in renal cancer cell prolifera-
tion and survival remains unclear. To investigate the role of EZH2
nuclear accumulation in RCC, we knock-down EZH2 in human re-
nal cancer cells by transfection with EZH2 targeting siRNA
(Fig. 3A–C). We found that depletion of EZH2 resulted in a de-
creased proliferation in ACHN, Caki1 and A498 renal cancer cell
lines (Fig. 3A). We did not ﬁnd an induction of apoptosis upon
depletion of EZH2 in renal cancer cells (data not shown). Because
EZH2 is a putative repressor of gene expression, we searched for
tumor suppressor genes which could be re-expressed upon deple-
tion of EZH2 in RCC. It has been reported that EZH2 can downregu-
late E-cadherin, p16(Ink4A), p21(CIP1,WAF1), p27Kip1, and APAF1
tumor suppressor genes [14,19]. After screening for potential
EZH2-regulated tumor suppressor genes, we found that only
p27Kip1 was re-expressed in ACHN and other renal cancer cell
lines upon depletion of EZH2 (Fig. 3C and data not shown). Consis-
tent with the known role of EZH2 in posttranslational histone
modiﬁcations, we found that depletion of EZH2 resulted in a de-
crease of histone H3 methylation in ACHN cancer cells (Fig. 3C).
These results suggest a positive role of EZH2 in renal cancer prolif-
eration and identify the tumor suppressor p27Kip1 as a new target
of EZH2 in RCC.
3.3. Re-expression of miR-101 depletes EZH2 expression in RCC cells
leading to decreased cancer cell proliferation
miR-101, one of microRNAs, has been reported as a negative
regulator of EZH2 [20,21]. Our search of TargetScanHuman [22]
database conﬁrmed two highly conserved target sequences of
miR-101 at position 59–65 and position 114–121 of EZH2 30 UTR.
Using TaqMan MicroRNA assay, we found very low expression of
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pared to expression of miR-101 in normal kidney (Fig. 4A). Relative
expression of miR-101 in clinical RCC samples ranged from 0.02 to
588 fold as compared to its normal counterpart (Fig. 4B). We found
a signiﬁcant decrease of miR-101 expression in 15 of 54 (28%) sur-
gically resected RCCs (Fig. 4B). Although we found lower expres-
sion of miR-101 in tumors than in its normal counterparts in 8 of
24 (33%) RCCs with EZH2 nuclear expression, these data were
not statistically signiﬁcant (Fig. 4C). Decreased miR-101 was signif-
icantly associated with younger patients’ age (Fig. 4D, p < 0.05) and
non-clear cell histology in RCC patients (Table 3, Fisher’s exact test
p = 0.0137, chi square 5.343).
To investigate the role of miR-101 in regulation of EZH2 aber-
rant expression in RCC, we transfected renal cancer cells with
miR-101 precursor. Re-expression of miR-101 led to a depletion
of EZH2, re-expression of EZH2-regulated p27Kip1 tumor suppres-
sor and suppression of renal cancer cell proliferation (Fig. 4E–G). It
is known that microRNAmay affect cellular protein levels by either
mRNA degradation or translational repression [23]. Using quanti-
tative RT-PCR, we found no changes in EZH2 mRNA expressionlevels after re-expression of miR-101 in ACHN and Caki1 renal can-
cer cells (Fig. 4H) whereas EZH2 protein expression was decreased
(Fig. 4E). These results suggest that miR-101 might downregulate
EZH2 expression through translational repression. Our results sug-
gest miR-101 as a negative regulator of EZH2 expression in renal
cancer cells.4. Discussion
Epigenetic repression of tumor-suppressor genes emerged as an
important mechanism of carcinogenesis [24]. Recent studies
showed that EZH2 is involved in epigenetic silencing of large num-
ber of genes via posttranslational modiﬁcation of histone H3 [8]
and direct control of DNA methylation [25]. EZH2 has been re-
ported to be involved in pathogenesis of multiple human malig-
nancies [8]. However, the role of EZH2 in human RCC remains
controversial [15,16,26,27].
In the present study, we demonstrated nuclear overexpression
of EZH2 in 48 of 110 (44%) surgically resected RCCs and in eight
AFor each cell line
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tential marker of renal cancer cells. Our study is the ﬁrst to show
aberrant nuclear expression of EZH2 in clinical RCC tissues by nu-
clear/cytosolic fractionation and Western immunoblotting. Our
ﬁndings are supported by Wagener et al. study showing overex-
pression of EZH2 by qRT-PCR at mRNA levels in 21 human RCCs
as compared to its normal counterparts [26] and immunohisto-
chemical staining of RCC tissue microarrays [15]. Together, our
studies suggest an overexpression of EZH2 at mRNA and protein
levels in RCCs. Our ﬁndings are further supported by other studies
demonstrating overexpression of EZH2 in human breast, prostate
and pancreatic cancers [10,12,14]. Consistent with our Western
blot ﬁndings of nuclear EZH2 in surgically resected RCCs, we found
nuclear accumulation of EZH2 selectively in cancer cells in clinical
RCC samples by immunohistochemical staining.
It is still unclear how EZH2 expression is regulated in human
cancer cells. EZH2 could be potentially regulated by miRNAs, small
RNA molecules which act as post-transcriptional regulators of a
gene expression. We are unaware of any previous report assessing
the role of miR-101 in the regulation of EZH2 expression in RCC.
Here, we provided evidences that re-expression of miR-101 down-
regulates EZH2 expression in renal cancer cells resulting in inhibi-
tion of cellular proliferation. We demonstrated that miR-101
expression is signiﬁcantly decreased in eight RCC cell lines and in
15 of 54 (28%) of surgical RCC tissues as compared to normal kid-
ney tissue. Although we found lower expression of miR-101 intumors than in its normal counterparts in 8 of 24 (33%) RCCs with
EZH2 nuclear expression, this data could not reach statistical sig-
niﬁcance. These results demonstrate a complexity of regulatory
network in which both miR-101 and EZH2 are involved suggesting
that miR-101 is probably not a sole negative regulator of EZH2
expression. There is another potential explanation of miR-101 po-
sitive expression in RCC tissues showing EZH2 nuclear accumula-
tion. RCC is notorious for the frequent presence of tumor
inﬁltrating immune cells [28]. Lymphocytes [29] and endothelial
cells [30] have been shown to express miR-101. Other miR-101-po-
sitive benign cells might contaminate surgically resected tumor
samples. There is a possibility that these normal cells in tumor
sample might bias the results of miR-101 expression due to high
sensitivity of PCR reaction which we used to analyze miR-101
levels.
In our study, we demonstrated that EZH2 nuclear accumulation
was strongly associated with increased tumor nuclear grade (Fuhr-
man grade), an indicator of high malignant potential in human
RCC. We showed that EZH2 nuclear staining is a marker of worse
overall and disease-speciﬁc survival in RCC patients. These data
is in agreement with Wagener et al. [15] study showing EZH2 nu-
clear overexpression as an independent unfavorable marker of can-
cer-speciﬁc survival in RCC patients. Contrary to our and Wagener
et al. [15] ﬁndings, Hinz et al. [16] reported that high mRNA levels
of EZH2 in human RCCs indicate less aggressive tumor phenotypes
with a favorable prognosis in RCC patients. This discrepancy in the
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Fig. 4. EZH2 is negatively regulated by miR-101 in renal cancer cells. Relative expression of miR-101 was measured by TaqMan MicroRNA Assay in RCC cell lines (A) and in
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612 T. Sakurai et al. / Biochemical and Biophysical Research Communications 422 (2012) 607–614evaluation of EZH2 as prognostic marker in RCC patients can be ex-
plained by different approaches (mRNA vs. protein expression)
applied to analysis of EZH2 expression in different studies. It is
known that microRNA may affect cellular protein levels by either
mRNA degradation or translational repression [23]. Here we dem-
onstrated that re-expression of miR-101 downregulates EZH2protein expression through translational repression while EZH2
mRNA levels were unchanged in renal cancer cells. Our ﬁndings
suggest that EZH2 protein expression could be suppressed by
miR-101 through translational repression even in case of EZH2
mRNA overexpression in the same RCC tumor in a certain cohort
of RCC patients. Although several studies utilized an analysis of
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Table 3
miR-101 decreased expression was associated with non-clear cell histology in RCC
patients.
miR-101 unchanged/
increased
miR-101
decreased
Clear cell histology 37 10
Non-clear cell
histology
2 5
Fisher’s exact test p = 0.0137, chi square 5.343.
T. Sakurai et al. / Biochemical and Biophysical Research Communications 422 (2012) 607–614 613EZH2 mRNA expression in human RCCs [16,26,27], our results sug-
gest that analysis of EZH2 protein expression is more reliable in
human RCCs and probably in other types of human cancer.
In our study, we demonstrated that EZH2 positively regulates
proliferation but not survival of renal cancer cells. These ﬁndingsare supported by our previous study of pancreatic cancer where
we found that EZH2 depletion suppressed proliferation with no ef-
fect on pancreatic cancer cell survival [14]. Our data are in agree-
ment with another study where EZH2 knockdown resulted in
decreased proliferation and cell cycle arrest without apoptosis in
prostate cancer cells [10]. Another study by Wagener et al. [26]
supports a speculation that EZH2 depletion might have an effect
on cancer cell survival in some RCC cell lines under certain condi-
tions, although the exact mode of such an effect remains to be
determined.
To investigate the mechanism of EZH2-mediated cancer cell
proliferation, we analyzed expression of tumor suppressor genes
which could be negatively regulated by EZH2 in renal cancer cells.
We identiﬁed p27Kip1, a cyclin-dependent kinase inhibitor, as a
new target gene of EZH2 in renal cancer cells. Moreover, re-expres-
sion of miR-101 resulted in EZH2 depletion, upregulation of
p27Kip1 and decreased renal cancer cell proliferation. Our results
614 T. Sakurai et al. / Biochemical and Biophysical Research Communications 422 (2012) 607–614suggest that EZH2 might contribute to renal cancer cell prolifera-
tion in part through epigenetic silencing of p27Kip1.
In summary, our study shows nuclear accumulation of EZH2 as
a prognostic marker of worse survival in human RCC, identiﬁes
EZH2 as a positive regulator of renal cancer cell proliferation, indi-
cates miR-101 as a negative regulator of EZH2 expression in renal
cancer cells, demonstrates p27Kip1 tumor suppressor as EZH2 tar-
get gene, and suggests EZH2 as a potential therapeutic target in the
treatment of human renal cancer. Future clinical approaches to in-
hibit EZH2 might include gene therapy using RNA interference and
reintroduction of EZH2-suppressing miRNAs in human RCC. In
view of EZH2 positive regulation of renal cancer cell proliferation,
development of EZH2 pharmacological inhibitors is an attractive
goal in future therapy of human RCC.
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